Q-omics provides the consensus-scored SEC22A profile across patient tissues and cancer cell-line models. SEC22A expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, SEC22A is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, SEC22A RNA expression shows 20,256 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, HNSC, and ACC as cancer lineages where SEC22A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SEC22A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SEC22A survival associations across molecular data types. SEC22A RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SEC22A RNA expression–survival associations across cancer types. High SEC22A expression shows unfavorable associations in KICH, ACC, LIHC, LGG, SCLC and STAD. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify KICH as the clearest survival context for SEC22A RNA expression.
This table summarizes SEC22A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 9. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SEC22A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SEC22A shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, BLCA and BRCA. The HNSC box plot shows higher SEC22A RNA expression in tumor versus normal tissue (log2 FC = +0.874, t-test p < 0.001).
This table shows molecular features associated with SEC22A in patient tissues and cancer cell lines. In patient samples, SEC22A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SEC22A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Leukemia.
